Splitting the pharmaceutical pie

Brand pharmaceutical companies sometimes agree to share profits from their patented drugs with generic manufacturers to keep rival products off the market. James Walsh and Lisa Huett consider the legality of these so-called reverse payments under Australian law in light of increasing attacks from antitrust authorities overseas